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What is the clinical utility of a 6-month computed
tomography in the follow-up of endovascular
aneurysm repair patients?
Michael R. Go, MD, Joel E. Barbato, MD, Robert Y. Rhee, MD, and Michel S. Makaroun, MD,
Pittsburgh, Pa
Objective: A drawback of endovascular aneurysm repair (EVAR) is the need for ongoing surveillance. Follow-up schedules
including 1-, 6-, and 12-month computed tomography (CT) established by regulatory trials have been carried into
clinical practice without critical assessment. The utility of a 6-month CT, with its associated radiation exposure and
contrast toxicity, obtained after a normal result at 1-month CT has not been established.
Methods: All EVAR patients from 1996 to 2004 at one institution with complete local 1-year follow-up were reviewed for
clinically significant CT findings at 1, 6, and 12 months. Before 2000, all patients underwent 1-, 6-, and 12-month CT.
In 2000, a policy of omitting the 6-month CT in patients who had a normal result on the 1-month scan was adopted.
Results: During the study period, 573 patients underwent EVAR, and 376 patients who had complete local 1-year
follow-up were included in this review. All had a 1-month CT scan and the result was abnormal in 40 (10.6%): five had
type 1 leaks (1.3%), 34 had type 2 leaks (9.0%), and one had a type 3 leak (0.3%); all were followed with 6-month CT. The
1-month CT scan result was normal for 336 (89.4%) patients. Of these, group I (130 patients, 67 treated after 2000)
underwent routine 6-month CT, with only two abnormalities noted (1.5%); both were type 2 endoleaks not associated
with sac growth. No 6-month CT in this group demonstrated findings warranting intervention. The 6-month CT was
omitted in group II (206 patients, all treated after 2000), and follow-up was only at 1 year. In this group, no patient’s
management would have been altered by findings on a 6-month CT. No patient in either group experienced aneurysm sac
growth by 1 year. Clinical complications occurred in three group I patients (2.3%): seroma, limb occlusion, and main
body thrombosis. Only one group II patient (0.5%) experienced a complication <1 year, a limb occlusion at 9 months.
Conclusions: After EVAR, a 6-month CT after a normal 1-month CT result does not identify any clinically significant
findings warranting intervention and can be omitted safely from the follow-up schedule. ( J Vasc Surg 2008;47:1181-7.)Unlike standard open repair, endovascular aneurysm
repair (EVAR) is associated with a unique set of complica-
tions, including endoleak, device migration, and material
fatigue, that mandate ongoing postoperative surveil-
lance.1-4 The early advantage of EVAR in mortality and
morbidity is clearly diminished by the frequency and ex-
pense of continued long-term testing and reinterventions.
Computed tomography (CT) with intravenous con-
trast remains the most common modality currently used at
most institutions in surveillance after EVAR. This regimen
is not, however, without drawbacks. Radiation exposure
after repeated scans can be significant.5 Often these patients
have coexisting risk factors for renal insufficiency that exac-
erbate contrast nephrotoxicity, and contrast nephropathy
can affect from 7% to 12% of patients after CT.6 Patients or
families must often miss work and travel long distances to
maintain their follow-up appointments. Finally, physicians,
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doi:10.1016/j.jvs.2008.01.056their office staffs, and the entire health care system are
strained by the excessive use of surveillance resources.2
The original EVAR regulatory trials, registries, and
device manufacturers recommended conservatively chosen
follow-up regimens, including CT scans with intravenous
contrast every 6 months, and sometimes every 3 months,
even if the result on the initial postoperative scan was
normal. These surveillance regimens including 1-, 6-, and
12-month CT in the first year have been carried into many
clinical practices without critical assessment, resulting in a
large number of scans that may not affect clinical decision
making and may not be necessary for appropriate patient
care.
Thresholds for intervention on abnormalities, such as
type 2 endoleaks, are changing, and so must our attempts
to identify them evolve.7,8 As the first step in an ongoing
effort to safely minimize the intensity and risk of EVAR
surveillance, we hypothesized that although a 6-month CT
may be indicated to monitor abnormalities identified on a
1-month CT, it can be omitted safely from the follow-up
schedule if the early CT scan result not identify any clini-
cally significant findings.
METHODS
The conduct of this study was approved by the Univer-
sity of Pittsburgh Institutional Review Board. A retrospec-
tive review of patients who underwent successful elective
EVAR at one University of Pittsburgh Medical Center
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local 1-year follow-up was performed. Study variables col-
lected included age, sex, size of aneurysm at repair, type of
endograft used, imaging at 1-, 6-, and 12-month follow-up
as applicable, and endograft-related complications up to 1
year out from surgery. All CT scans were re-reviewed for
this study tomeasure aneurysm sac size using theminor axis
method9 and to identify the presence of any complication
including endoleak, device migration, or other graft abnor-
malities.
Before 2000, all patients underwent 1-, 6-, and 12-
month visits with routine CT scanning in conjunction with
abdominal radiographs. In 2000, a policy of omitting the
6-month return visit as well as the CT scan in patients who
had a normal result on the 1-month CT scan was adopted.
This policy was applied mostly for postmarketing EVAR
procedures but not for patients enrolled in protocols that
continued to dictate a more frequent follow-up. Patients
with abnormal findings at 1 month all returned for a
6-month follow-up and CT imaging. Two groups of pa-
tients with normal findings at 1 month were compared.
Group I included those who underwent routine 6-month
follow-up, and group II patients omitted the 6-month
evaluation and returned for a 1-year visit (Fig 1). Mean age,
sex, mean aneurysm size, and device types used were iden-
tified in each group. Computed tomography abnormali-
ties found at each time point, device-related complica-
tions up to 1-year follow-up, and reinterventions up to
1-year follow-up were compared between the two
Fig 1. Protocol for computed tomography (CT) surveillance af-
ter endovascular aneurysm repair (EVAR), including number and
types of endoleak at each follow-up patients in group I, group II,
and those with abnormal results on 1-month CT scans.groups.RESULTS
During the study period, 573 patients underwent
EVAR at one institution. Seven patients were excluded
because they died from non-aneurysm-related causes 1
year, another 29 were lost to follow-up by 1 year, and 161
patients underwent follow-up CT at other institutions
and were excluded because those scans could not be
re-reviewed for this study.
The remaining 376 patients (66%) with complete local
1-year follow-up were included in this report. The propor-
tion of included patients was the same before and after
2000. Group I had 130 patients (67 after 2000) and group
II had 206 patients (all after 2000). The mean age of the
study patients was 74 years (range, 52-91 years), and 85%
were men. Mean minor axis diameter of the aneurysms was
56 mm (range, 40-93 mm). The baseline distribution
among group I, group II, and the patients with abnormal
1-month CT scan results is reported in the Table. Although
all three were similar in terms of age, sex, and aneurysm
size, there was heterogeneity as far as the types of en-
dografts used in each group. Three different endografts
were equally used during their phase II trials in group I, but
the Ancure (Guidant, Indianapolis, Ind) device was over-
represented in group II subsequent to its postmarket re-
lease.
Of the 376 total EVAR patients, 40 (10.6%) had an
abnormality on their 1-month CT scan (Fig 1). Five pa-
tients had type 1 endoleaks (1.3%), 34 had type 2 (9%), and
one patient had a type 3 endoleak (0.3%). Of those patients
with an abnormal CT result at 1 month, 64% also had an
abnormal result at 6 months.
The major focus of this study, however, is the 336
patients (89.4%) with a normal 1-month CT result. Of
these, 130 (group I) underwent routine 6-month
follow-up with a CT scan, whereas 206 (group II) omitted
the 6-month visit and CT and were followed up only at 1
year (Fig 1). Fifty two percent of the group I patients were
treated after 2000 and were generally trial patients whose
protocols mandated a 6-month CT. All group II patients
were treated postmarketing after 2000.
Group I. Only two of the 130 patients in group I
(1.5%) had an abnormal CT result at 6 months (Fig 1).
Both were new type 2 endoleaks, and neither was asso-
ciated with sac growth. There were no instances of device
migration, disconnection, or other device failure. More
important, no interventions were performed on any of
these patients as a result of the findings of the 6-month
follow-up.
At 1 year, all patients returned for follow-up, but only
126 of the 130 group I patients had a CT scan. Four were
not scanned for a variety of reasons, including new contrast
allergy, renal insufficiency, and scheduling conflicts. At 1
year, four patients had abnormal CT results (Fig 1). One
patient had a proximal type 1 endoleak that was not evident
at 6 months and was repaired successfully with the place-
ment of a proximal extension cuff. Images of the attach-
ment site from this patient’s 1-, 6-, and 12-month CT scans
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2 endoleaks, one persistent from 6 months and two newly
diagnosed. None were associated with sac growth. Of the
two type 2 endoleaks noted at 6 months, one had appar-
ently resolved spontaneously; again, no device migration or
other failure had occurred. The repair of the type 1 leak
represented the only intervention performed in this group
on the basis of the 12-month CT.
Three clinically significant device- or procedure-related
complications occurred in group I by 1-year follow-up
(2.3%). One patient had a groin seroma that became clini-
cally evident at 6 months and was drained because it be-
came symptomatic. A second patient presented with
thrombosis of the main body of her endograft at 7 months,
which was treated with an axillary–bifemoral bypass. This
patient had a TriVascular (Trivascular, Santa Rosa, Calif)
device and had no evidence of kinking or stenosis in the
device at 6 months (Fig 3). A considerable amount of sac
shrinkage was noted, however, with the minor axis decreas-
ing from 54 to 38 mm. It is not clear if this extensive
remodeling continued beyond 6 months and contributed
to the thrombosis. In the last patient, thrombosis devel-
oped in one limb of his endograft at 1 year requiring a
cross-femoral bypass, again with no abnormalities at the
6-month assessment (Fig 4).
Group II. Group II consisted of the 206 patients who
had normal 1-month CT scans and proceeded to 12
months before their next surveillance imaging. At 12
months in this group, seven abnormal CT scans were
identified (Fig 1), all of which were new type 2 endoleaks.
None were associated with sac growth, and there were no
instances of device migration or other failure. As dictated
by treatment policies at the time, which have since changed,
Table. Distribution of age, sex, aneurysm size, and device
patients with abnormal 1-month computed tomography sc
Variable Group I (n  130)
Age, mean years 73.0
Male, % 83.1%
Minor axis aneurysm diameter, mean mm 54.3
No. (%) repaired with each device type
Ancureb 48 (36.9)
Excluderc 37 (28.5)
Lifepathd 28 (21.5)
AneuRxe 2 (1.5)
Zenithf 2 (1.5)
TriVascularg 6 (4.6)
Quantumh 4 (3.0)
Talente 1 (0.7)
aValues refer to comparisons between group I and group II. P value  0.05
bGuidant, Indianapolis, Ind.
cW. L. Gore and Assoc., Flagstaff, Ariz.
dEdwards Lifesciences, Irvine, Calif.
eMedtronic, Minneapolis, Minn.
fCook, Bloomington, Ind.
gTriVascular, Santa Rosa, Calif.
hCordis, Miami Lakes, Fla.two of these type 2 endoleaks were coiled, one successfully,and the rest of the endoleaks all eventually resolved spon-
taneously.
Only one patient in group II had a clinically significant
complication by 1 year (0.5%). This patient had a unilateral
unsupported Ancure limb thrombosis at 9 months that was
treated with lysis and then placement of a Wallstent (Bos-
ton Scientific, Natick, Mass) at an area of stenosis in the
affected limb.
DISCUSSION
Late device failures and poor aneurysm exclusion in
EVAR patients may lead to ruptures and late complications.
Follow-up schedules should be tailored both in method
and frequency to maximize the yield of clinically significant
findings while reducing risks, costs, and collection of infor-
mation that does not affect patient management. Initial
abnormalities are typically noted in 10% to 15% of pa-
tients,10 mostly type 2 endoleaks, and were present in only
11% of our patients. Clearly, closer follow-up of this minor-
ity of patients may be justifiable, but the policy of extending
the same close scrutiny to all patients has not been evalu-
ated until this review. The yield of abnormalities on a
6-month CT after a normal 1-month CT result is only
1.5%, and none were clinically significant. Omitting the
6-month CT in group II did not result in any untoward
effect in 200 patients, casting serious doubt on the
appropriateness of such routine testing.
Some caveats to our results are important to highlight
given the design of this study. Clearly, inclusion in group I
or group II was not based not on randomization but on the
surveillance practice of our institution at the time. Further-
more, many group I patients were part of ongoing EVAR
trials, whereas all group II patients were by necessity treated
used among group I, group II, and the group of
oup II (n  206) Pa
Patients with abnormal 1-month
CT scans (n  40)
74.0 0.22 74.2
86.9% 0.71 87.5%
54.0 0.75 55.0
173 (83.9) .0076 26 (65.0)
5 (2.4) .0001 2 (5.0)
1 (0.5) .0001 4 (10.0)
18 (8.7) .007 3 (7.5)
9 (4.4) 0.21 4 (10.0)
0 (0.0) .003 0 (0.0)
0 (0.0) .02 1 (2.5)
0 (0.0) .0001 0 (0.0)
onsidered significant.type
ans
Gr
was cin the postmarketing phase. Both of these factors may
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two groups as far as indications for stent grafting, anatomic
morphology, and patient comorbidities. However, if any-
thing, EVAR trial patients were over-represented in group
I; with more recent patients, after market release, forming
all of group II. This suggests that even withmore aggressive
application of EVAR, the group II patients did not suffer
from omission of the 6-month CT.
The variety of EVAR devices used in our patients and
the lack of uniform distribution between groups may be
pertinent as well. The over-representation of the Ancure
device in group II was due to the early United States Food
and Drug Administration (FDA) approval process of this
device. This may lead to an interpretation that the omission
of the 6-month scan is only safe in patients with an Ancure
Fig 2. Proximal attachment site in the group I patient w
(C) at 1 year when the leak developed.device; however, the paucity of findings in all device types atthe 6-month interval after a negative 1-month CT in group
I suggests otherwise. We have eliminated the 6-month
follow-up evaluation from all other devices since with sim-
ilar results.
The recommended practice of following up EVAR
patients with CT scans at 1, 6, and 12 months in the first
year is part of the instructions for use of all marketed
devices, carried through from the regulatory trials. Lim-
ited data have been published on the efficacy of this
regimen. In fact, after examining the European Collab-
orators on Stent/Graft Techniques for Aortic Aneurysm
Repair (EUROSTAR) registry, Leurs et al11 concluded
that EVAR patients who were compliant with a high-
intensity follow-up regimen had more EVAR complica-
tions than those who were less compliant with their
veloped a type 1 leak at (A) 1month, (B) 6months, andho desurveillance regimen. Although such an analysis of this
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relationship between intensity of surveillance and risk of
EVAR complications remains largely unknown. In fact, it
may be that the optimal surveillance regimen is patient-
and device-specific.
Fairman et al12 reported that the presence of any en-
doleak is a predictor for aneurysm sac expansion by the time
of 6-month follow-up, highlighting the importance of the
6-month CT in this population. However, most of these
are type 2 endoleaks, which follow a relatively benign
Fig 3. The 6-month computed tomography scan of the group I
patient who developed main body thrombosis showed no evidence
of stenosis at the narrowest portion of the aorta.
Fig 4. The 6-month computed tomography scan of the group I
patient who developed limb thrombosis showed no evidence of
stenosis at the narrowest portion of the aorta.course when not associated with sac growth, suggestingthat a modified follow-up schedule may be suitable even in
this population.7,8
In group II, the 6-month follow-up visit as well as the
CT scan was omitted. In the entire study population, four
clinically significant complications occurred 1 year. A
6-month visit was of value only in detecting the seroma in
group I, which was a prominent complaint of the patient
and would have probably been reported in the absence of a
routine visit. Most recent patients are now treated com-
pletely percutaneously, which should decrease the inci-
dence of this complication. A 6-month visit may have been
of value in detecting the one limb occlusion that occurred
at 9 months in group II had it been performed. However, a
6-month visit was performed before the two device occlu-
sions occurred in group I and was obviously of no value in
preventing those complications. Both patients in group I
who had device occlusions had palpable femoral pulses and
no symptoms of lower extremity insufficiency at their
6-month visit.
This study focused on the first year of follow-up only,
but it is interesting and not surprising to note that a small
but significant number of complications occurred1 year.
The occurrence of these late complications suggests that
although we have shown that elimination of a 6-month CT
in these patients is safe, it remains mandatory to continue
some form of indefinite surveillance, although the optimal
intensity of late follow-up remains unknown.
Although most centers still rely on CT angiography for
the follow-up of their EVAR patients, novel modalities for
surveillance are emerging. The utility of duplex ultrasound
with and without contrast enhancement for the detection
of endoleaks has been studied by several groups and prom-
ises to provide a nephrotoxin-free method for detecting
EVAR complications.13 It may ultimately prove to be even
more sensitive than CT, given its ability to detect subtle
flow characteristics within an aneurysm sac, which with CT
requires multiple scans at different contrast times to be
detected. We and others have previously described ultra-
sound imaging to be an accurate method to detect sac
expansion, perhaps the most important marker for ongoing
risk of rupture.14 Despite our original skepticism regarding
the effective detection of endoleaks in hospital laboratories,
we have updated our ultrasound equipment and moved the
studies into an office-based laboratory, relying more on this
modality than in previous reports.
Although its long-term utility is still being investigated,
measurement of intrasac pressure using an implantable
transducer has shown promise in identifying endoleaks and
may provide a marker that is easier to interrogate more
frequently.15
CONCLUSION
Advantages of EVAR compared with traditional
open aneurysm repair in terms of patient quality of life
and cost-effectiveness may be abrogated by intensive
surveillance regimens. Furthermore, CT angiography as
a follow-up modality incurs risk of contrast toxicity and
radiation exposure. This study suggests that elimination
JOURNAL OF VASCULAR SURGERY
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patients is safe because it does not identify any significant
clinical findings. Further study of alternative surveillance
modalities and the natural history of late EVAR compli-
cations may identify safer, less frequent follow-up regi-
mens for some subgroups of EVAR patients.
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Dr Hasan Dosluoglu (Buffalo, NY). In my practice, I have
omitted the 1-month scan altogether if I am happy with the
completion angiogram at the end of the procedure, because the
studies show that most of these type 2 endoleaks, especially, will go
away in 6months. So why can’t we do the exact reverse of what you
did, and omit the first month CT and get the first one at 6 months
and maybe go from there?
Dr Michael R. Go. Probably the most important reason to
obtain the 1-month computed tomography (CT) is the 11% of
patients who, in our hands, have an abnormality on that scan
after EVAR. Almost all had no abnormalities on their comple-
tion angiograms. In fact, there were five type 1 endoleaks and
one type 3 endoleak noted on 1-month scans in our study, all of
which would require immediate intervention by today’s stan-
dards.
Dr Keith Calligaro, (Philadelphia, Pa). A comment and a
question. I think that in your last slide, the conclusion should be
that a CT scan is not necessary at 6 months for Ancure grafts. The
vast majority of your grafts were Ancure, and the remaining
numbers were so small, I don’t know if you can make that conclu-
sion about those other type of grafts. My question is whether you
are still doing CT scans as follow-up? We’ve stopped doing routine
CT scans and just do duplex scan surveillance. If the first CT scan
is normal, we will follow up with duplex scans only, unless aDr Go. There were a significant number of patients who did
not have Ancure grafts, 63% in group I. But you are right, that
number was only 26% in group II. And as we find out more and
more that EVAR outcomes, and probably complications, are
device-specific, your point is well taken. The frequency of positive
findings at 1 month is equivalent, which would allow us to extend
the recommendations to all grafts. As you mention, we agree that
duplex can be substituted for CT once the aneurysm fails to
expand; this requires a couple of CT scans and does not apply
necessarily to the first year of follow-up, which is the focus of this
paper. Our current policy is similar to yours.
Dr Clifford Buckley (Temple, Tex). We have come to the
same conclusion. We have reviewed 4-year follow-up of 424 pa-
tients between our own institution and the UT Southwestern in
Dallas, using a combined database. The distribution of the grafts
was fairly equal between all of the four major players—Cook,
Medtronic, Gore, and Ancure. The number of abnormal findings
in patients who had one normal CT scan was extremely low. The
number of interventions that were required was extremely low. It
made us look at whether we were gaining anything at all from the
intensity of the follow-up. It appears that we gained very little.
Most of the patients who required an intervention came for an
unscheduled evaluation with new symptoms. If they had aneurysm
sac enlargement, they came in with complaints of abdominal pain
or back pain. People who had graft limb occlusions came in
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yielded very little information affecting patient care.
Dr Go. That is similar to our findings here. However, our
current data only apply to the first year of follow-up and cannot be
extrapolated to late follow-up, where a small number of patients
still present with asymptomatic findings requiring treatment.
Dr Mark Fillinger (Lebanon, NH). I appreciate your paper
and it was a nice study. I think I agree with your conclusions, but
I just wanted to sound a couple notes of caution. One was your
conclusion that the 6-month was of no value, period. But actually
what you showed was there was no value if you had a normal
1-month CT, which was the majority of the patients.
The other caution is using “no change in diameter” as your
criteria for “no problems.” If you look at the Gore Pivotal Clinical
trial, the vast majority of patients had no enlargement at 1 year by
diameter, and yet we now know that over a third of them were
already enlarging by volume at that point. So you have to be
cautious about using an insensitive parameter to declare that there
is no present or future problem.
Dr Go.We agree that the 6-month CT is of little significance
only when the 1-month CT is normal. Since a 1-year CT is still in
our algorithm and we use a significant change of 5 mm in diameter
as our threshold, we do not see the utility of a more sensitive
longitudinal parameter.
Dr Roger Greenhalgh (London, United Kingdom). I
thought the paper was a very useful contribution, and the infor-
mation given us about the 6-month CT scan is a very helpful piece
in the jigsaw. I think it is important to put this into perspective. We
have gone through an era of the trials and during this decade of the
trials, we have had to adopt a very, very careful attitude to this then
new technique. CT scan was the agreed method of checking and
during the trial period, we got used to using CT scans, frequently
at first and annually.I think we are moving away from the early experience, and it
then becomes relevant to look at different health systems in the
different parts of the world. The issue that you do not have in the
United States to the same extent as in certain parts of Europe and
Scandinavia and Britain with their National Health Service is this
irritating matter of cost-effectiveness. Cost-effectiveness is some-
thing that our governments and the authorities will take into
account and they will measure the benefit of EVAR against the
various drawbacks against that benefit. One of the most important
costs is the CT scan. An annual CT scan would seem to be high
priority to lose in the follow-up for cost-effectiveness to have any
hope of success. That is the background for my question.
But my question is, can you examine your data to look and see
if you could, in retrospect, have done without your annual, 1-year
CT scan? Could you have used other modalities to find those issues
reliably without CT scan? Because if you can, that will be the
beginning of a potential cost-effective future for EVAR.
Dr Go. Certainly, any advantage of EVAR over open repair in
terms of cost-effectiveness is abrogated in the long-term by the
need for this ongoing surveillance. Thus, we have been moving
toward ultrasound surveillance. It would be possible to reanalyze
our database beyond 1 year, and this is one of the next steps in our
ongoing effort at University of Pittsburgh to pare down the
surveillance regimen.
Dr Alan B. Lumsden (Houston, Tex). I think one of the
exciting opportunities in imaging is that all of the new systems
which we’re installing will do fluoro-CT. We are going to have the
opportunity in an operating room after the anticoagulation is
reversed to do our ownCT scans. And the question then is, wemay
not need a follow-up CT scan for 2 or 3 years, but it is going to put
CT scanning in the operating room, basically, under a certain
semblance of control of the surgeons.
